The timelines for the evaluation are to be confirmed. 08 April 2022 Following a routing challenge raised by the company, regarding the Topic Selection Oversight Panel’s decision to route maralixibat ...

Mirum's $400,000-a-year oral drug Livmarli, or maralixibat, was approved in September 2021 to treat Alagille syndrome, a condition that includes persistent itch and a variety of heart and bone issues.

Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution ... of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe ...